{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:04:02Z","timestamp":1792699442601,"version":"4.5.0"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2020.554899","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T01:42:20Z","timestamp":1603417340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniela","family":"Rodrigues-Amorim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Spuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rivera-Baltan\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-770","article-title":"Pain as a global public health priority","volume":"11","author":"Goldberg","year":"2011","journal-title":"BMC Public Health."},{"key":"B2","first-page":"537","article-title":"Depression: a major public health problem in need of a multi-sectoral response","volume":"136","author":"Jacob","year":"2012","journal-title":"Indian J Med Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11121-011-0231-8","article-title":"The public health impact of major depression: a call for interdisciplinary prevention efforts","volume":"12","author":"McLaughlin","year":"2011","journal-title":"Prev Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41398-019-0460-3","article-title":"Prognosis and improved outcomes in major depression: a review","volume":"9","author":"Kraus","year":"2019","journal-title":"Transl Psychiatry."},{"key":"B5","first-page":"6","article-title":"Depression: underdiagnosed, undertreated, underappreciated","volume":"13","author":"Sheehan","year":"2004","journal-title":"Manag Care."},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B7","first-page":"24","article-title":"Generalized anxiety and depression in primary care: prevalence, recognition, and management","volume":"63","author":"Wittchen","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12875-015-0358-y","article-title":"Generalized anxiety disorder in primary care: mental health services use and treatment adequacy","volume":"16","author":"Roberge","year":"2015","journal-title":"BMC Fam Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/S0140-6736(06)69865-6","article-title":"Generalised anxiety disorder","volume":"368","author":"Tyrer","year":"2006","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/9724371","article-title":"The link between depression and chronic pain: neural mechanisms in the brain","volume":"2017","author":"Sheng","year":"2017","journal-title":"Neural Plast."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1526-4637.2004.04019.x","article-title":"Comorbidities in chronic neuropathic pain","volume":"5","author":"Nicholson","year":"2004","journal-title":"Pain Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bbi.2016.04.012","article-title":"Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation?","volume":"56","author":"Fiore","year":"2016","journal-title":"Brain Behav Immun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40122-017-0088-z","article-title":"A review of the emotional aspects of neuropathic pain: from comorbidity to co-pathogenesis","volume":"6","author":"Torta","year":"2017","journal-title":"Pain Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/j.pain.0000000000000827","article-title":"Chronic stress exacerbates neuropathic pain via the integration of stress-Affect-related information with nociceptive information in the central nucleus of the amygdala","volume":"158","author":"Li","year":"2017","journal-title":"Pain."},{"key":"B16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/AJP.0000000000000354","article-title":"Fibromyalgia and chronic pain syndromes: a white paper detailing current challenges in the field","volume":"32","author":"Arnold","year":"2016","journal-title":"Clin J Pain."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6584753","article-title":"Chronic widespread pain and fibromyalgia syndrome: life-course risk markers in young people","volume":"2019","author":"Tan","year":"2019","journal-title":"Pain Res Manag."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8269564","article-title":"Subjective experiences and sensitivities in women with fibromyalgia: a quantitative and comparative study","volume":"2018","author":"De Roa","year":"2018","journal-title":"Pain Res Manag."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/486590","article-title":"Fibromyalgia and depression","volume":"2012","author":"Gracely","year":"2012","journal-title":"Pain Res Treat."},{"key":"B20","first-page":"815","article-title":"Fibromyalgia and anxiety disorder","volume":"88","author":"Thorlacius","year":"2002","journal-title":"Laeknabladid."},{"key":"B21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fnhum.2019.00138","article-title":"Differential neuroplastic changes in fibromyalgia and depression indexed by up-regulation of motor cortex inhibition and disinhibition of the descending pain system: an exploratory study","volume":"13","author":"Cardinal","year":"2019","journal-title":"Front Hum Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.22921","article-title":"Anxiety and depression associated with urinary incontinence. a 10-year follow-up study from the Norwegian HUNT study (EPINCONT)","volume":"36","author":"Felde","year":"2017","journal-title":"Neurourol Urodyn."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMcp0707023","article-title":"Urinary stress incontinence in women","volume":"358","author":"Rogers","year":"2008","journal-title":"N Engl J Med."},{"key":"B24","first-page":"259","article-title":"Duloxetine in the treatment of stress urinary incontinence","volume":"1","author":"Jost","year":"2005","journal-title":"Ther Clin Risk Manag."},{"key":"B25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/nedt.2007.3.2.193","article-title":"Duloxetine in the treatment of major depressive disorder","volume":"3","author":"Goldstein","year":"2007","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/JPR.S4462","article-title":"Duloxetine for the management of fibromyalgia syndrome","volume":"2","author":"Scholz","year":"2009","journal-title":"J Pain Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/IJGM.S4492","article-title":"Duloxetine in the treatment of generalized anxiety disorder","volume":"2","author":"Wright","year":"2009","journal-title":"Int J Gen Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.clinthera.2018.04.001","article-title":"Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy","volume":"40","author":"Iqbal","year":"2018","journal-title":"Clin Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpsychires.2020.02.022","article-title":"Duloxetine and cardiovascular adverse events: a systematic review and meta-analysis","volume":"124","author":"Park","year":"2020","journal-title":"J Psychiatr Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4088\/PCC.v08n0404","article-title":"The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials","volume":"8","author":"Nelson","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1111\/j.1526-4637.2006.00178.x","article-title":"Duloxetine and other antidepressants in the treatment of patients with fibromyalgia","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2165\/00023210-200923060-00006","article-title":"Duloxetine: a review of its use in the treatment of generalized anxiety disorder","volume":"23","author":"Carter","year":"2009","journal-title":"CNS Drugs."},{"key":"B33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.semarthrit.2008.11.001","article-title":"Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia","volume":"39","author":"Mease","year":"2010","journal-title":"Semin Arthritis Rheum."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00004850-199705000-00003","article-title":"An open-label study of duloxetine hydrochloride, a mixed sertotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder","volume":"12","author":"Berk","year":"1997","journal-title":"Int Clin Psychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","article-title":"Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine","volume":"24","author":"Goldstein","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4088\/JCP.v63n0407","article-title":"Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial","volume":"63","author":"Detke","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4088\/JCP.v63n0309","article-title":"Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial","volume":"63","author":"Goldstein","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1176\/appi.psy.46.4.345","article-title":"Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years","volume":"46","author":"Burt","year":"2005","journal-title":"Psychosomatics."},{"key":"B40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"Eur Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1192\/bjp.188.4.346","article-title":"Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study","volume":"188","author":"Perahia","year":"2006","journal-title":"Br J Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpsychires.2007.01.008","article-title":"A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder","volume":"42","author":"Perahia","year":"2008","journal-title":"J Psychiatr Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4088\/JCP.v69n0113","article-title":"Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques","volume":"69","author":"Perahia","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4088\/JCP.08m04756","article-title":"Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Perahia","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jpsychires.2005.06.005","article-title":"Management of depression relapse: re-initiation of duloxetine treatment or dose increase","volume":"40","author":"Fava","year":"2006","journal-title":"J Psychiatr Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.4088\/JCP.v68n1110","article-title":"Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial","volume":"68","author":"Brecht","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1440-1819.2007.01666.x","article-title":"Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil","volume":"61","author":"Lee","year":"2007","journal-title":"Psychiatry Clin Neurosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.4088\/JCP.09m05723blu","article-title":"Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial","volume":"72","author":"Brecht","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1185\/030079907X188107","article-title":"Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder","volume":"23","author":"Pigott","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"B50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/ajp.2007.164.6.900","article-title":"Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial","volume":"164","author":"Raskin","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/jcp.0b013e318160738e","article-title":"Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder","volume":"28","author":"Raskin","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/j.1742-1241.2007.01476.x","article-title":"The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity","volume":"61","author":"Wise","year":"2007","journal-title":"Int J Clin Pract."},{"key":"B53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4088\/JCP.v69n0317","article-title":"Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability","volume":"69","author":"Karp","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4088\/JCP.v69n0905","article-title":"A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy","volume":"69","author":"Kornstein","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4088\/JCP.v69n0912","article-title":"An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache","volume":"69","author":"Volpe","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.psychres.2010.03.006","article-title":"Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder","volume":"177","author":"Herrera-Guzm\u00e1n","year":"2010","journal-title":"Psychiatry Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/0269881109104863","article-title":"Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels","volume":"24","author":"Volonteri","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1742-1241.2010.02546.x","article-title":"Attributes of response in depressed patients switched to treatment with duloxetine","volume":"65","author":"Sagman","year":"2011","journal-title":"Int J Clin Pract."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1185\/03007995.2011.609539","article-title":"A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms","volume":"27","author":"Gaynor","year":"2011","journal-title":"Curr Med Res Opin."},{"key":"B60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/YIC.0b013e32834ce11b","article-title":"A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode","volume":"27","author":"Martinez","year":"2012","journal-title":"Int Clin Psychopharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hup.1262","article-title":"Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol","volume":"27","author":"Oakes","year":"2012","journal-title":"Hum Psychopharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jad.2011.07.026","article-title":"A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression","volume":"136","author":"Rosso","year":"2012","journal-title":"J Affect Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jagp.2013.01.019","article-title":"Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo","volume":"22","author":"Robinson","year":"2014","journal-title":"Am J Geriatr Psychiatry."},{"key":"B64","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/hup.2447","article-title":"Are antidepressants equally effective in the long-term treatment of major depressive disorder?","volume":"30","author":"Buoli","year":"2015","journal-title":"Hum Psychopharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40261-016-0399-6","article-title":"Comparing the effects of sertraline with duloxetine for depression severity and symptoms: a double-blind, randomized controlled trial","volume":"36","author":"Mowla","year":"2016","journal-title":"Clin Drug Investig."},{"key":"B66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pnpbp.2019.01.001","article-title":"Duloxetine plasma level and antidepressant response","volume":"92","author":"De Donatis","year":"2019","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/gps.4088","article-title":"Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Alaka","year":"2014","journal-title":"Int J Geriatr Psychiatry."},{"key":"B68","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hup.1211","article-title":"Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder","volume":"26","author":"Bodkin","year":"2011","journal-title":"Hum Psychopharmacol Clin Ext."},{"key":"B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hup.1172","article-title":"An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with generalized anxiety disorder","volume":"26","author":"Pier\u00f2","year":"2011","journal-title":"Hum Psychopharmacol Clin Ext."},{"key":"B70","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wu","year":"2011","journal-title":"Chin Med J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder : examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"Nicolini","year":"2009","journal-title":"Psychol Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/0269881108091588","article-title":"A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder","volume":"22","author":"Allgulander","year":"2008","journal-title":"J Psychopharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hup.949","article-title":"Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies","volume":"23","author":"Davidson","year":"2008","journal-title":"Hum Psychopharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jpsychires.2008.02.002","article-title":"Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint","volume":"42","author":"Pollack","year":"2008","journal-title":"J Psychiatr Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20337","article-title":"Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms","volume":"25","author":"Russell","year":"2008","journal-title":"Depress Anxiety."},{"key":"B76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depress Anxiety."},{"key":"B77","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder : results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"Int Clin Psychopharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clin Drug Investig."},{"key":"B79","first-page":"32","article-title":"Effectiveness of pregabalin compared to duloxetine in diabetic peripheral neuropathic pain: an observational study","volume":"67","author":"Jha","year":"2019","journal-title":"J Assoc Physicians India."},{"key":"B80","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","journal-title":"Cancer Chemother Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/ALN.0000000000000902","article-title":"Efficacy of duloxetine in chronic low back pain with a neuropathic component a randomized, double-blind, placebo-controlled crossover trial","volume":"124","author":"Schukro","year":"2016","journal-title":"Anesthesiology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jdi.12361","article-title":"Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study","volume":"7","author":"Yasuda","year":"2016","journal-title":"J Diabetes Investig."},{"key":"B83","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/ijcp.12641","article-title":"Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo","volume":"69","author":"Gao","year":"2015","journal-title":"Int J Clin Pract."},{"key":"B84","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/AJP.0000000000000057","article-title":"Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain results from a german observational study","volume":"30","author":"Happich","year":"2014","journal-title":"Clin J Pain."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/ijcp.12452","article-title":"Comparative safety and tolerability of duloxetine vs. pregabalin vs duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain","volume":"68","author":"Irving","year":"2014","journal-title":"Int J Clin Pract."},{"key":"B86","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/papr.12127","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis","volume":"14","author":"Vollmer","year":"2014","journal-title":"Pain Pract."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? the cOMBO-DN study - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care."},{"key":"B90","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4065\/mcp.2010.0681","article-title":"Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison","volume":"86","author":"Tanenberg","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"B91","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/dmrr.1000","article-title":"Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain","volume":"25","author":"Skljarevski","year":"2009","journal-title":"Diabetes Metab Res Rev."},{"key":"B92","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1526-4637.2007.00276.x","article-title":"Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes","volume":"8","author":"Armstrong","year":"2007","journal-title":"Pain Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1526-4637.2006.00258.x","article-title":"An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic","volume":"8","author":"Wernicke","year":"2007","journal-title":"Pain Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1526-4637.2006.00207.x","article-title":"Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study","volume":"7","author":"Raskin","year":"2006","journal-title":"Pain Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain."},{"key":"B96","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin","year":"2005","journal-title":"Pain Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/14397595.2016.1245237","article-title":"An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia","volume":"27","author":"Murakami","year":"2017","journal-title":"Mod Rheumatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0718-y","article-title":"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients","volume":"17","author":"Murakami","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/PSY.0b013e31825b9855","article-title":"The effect of duloxetine treatment on cognition in patients with fibromyalgia","volume":"74","author":"Mohs","year":"2012","journal-title":"Psychosom Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/AJP.0b013e318197d4e4","article-title":"Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder","volume":"25","author":"Arnold","year":"2009","journal-title":"Clin J Pain."},{"key":"B101","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia","volume":"25","author":"Chappell","year":"2009","journal-title":"Clin. J. Pain."},{"key":"B102","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain."},{"key":"B103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B105","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2010.10.031","article-title":"Duloxetine for mild to moderate postprostatectomy incontinence: Preliminary results of a randomised, placebo-controlled trial","volume":"59","author":"Cornu","year":"2011","journal-title":"Eur Urol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1185\/03007990903438295","article-title":"Short-and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence","volume":"26","author":"Cardozo","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"B107","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/nau.20471","article-title":"Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence","volume":"27","author":"Bent","year":"2008","journal-title":"Neurourol Urodyn."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-8-2","article-title":"Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial","volume":"8","author":"Lin","year":"2008","journal-title":"BMC Urol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.maturitas.2008.04.012","article-title":"Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence","volume":"60","author":"Schagen van Leeuwen","year":"2008","journal-title":"Maturitas."},{"key":"B110","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00192-006-0256-x","article-title":"Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence","volume":"18","author":"Castro-Diaz","year":"2007","journal-title":"Int Urogynecol J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.eururo.2006.01.038","article-title":"Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy","volume":"49","author":"Schlenker","year":"2006","journal-title":"Eur Urol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1185\/030079906X148337","article-title":"Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations)","volume":"22","author":"Weinstein","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/01.ju.0000154167.90600.c6","article-title":"A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence","volume":"173","author":"Ghoniem","year":"2005","journal-title":"J Urol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00192-004-1270-5","article-title":"Impact of duloxetine on quality of life for women with symptoms of urinary incontinence","volume":"16","author":"Kinchen","year":"2005","journal-title":"Int Urogynecol J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/01.AOG.0000134525.86480.0f","article-title":"Pharmacological treatment of women awaiting surgery for stress urinary incontinence","volume":"104","author":"Cardozo","year":"2004","journal-title":"Obstet Gynecol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1464-410X.2004.04607.x","article-title":"Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial","volume":"93","author":"Millard","year":"2004","journal-title":"BJU Int."},{"key":"B117","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1471-0528.2004.00067.x","article-title":"Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence","volume":"111","author":"Van Kerrebroeck","year":"2004","journal-title":"BJOG An Int J Obstet Gynaecol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1097\/01.ju.0000080708.87092.cc","article-title":"Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence","volume":"170","author":"Dmochowski","year":"2003","journal-title":"J Urol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/AJP.0b013e3181dee80e","article-title":"Pain response profile of patients with fibromyalgia treated with duloxetine","volume":"26","author":"Bradley","year":"2010","journal-title":"Clin J Pain."},{"key":"B120","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and metaanalyses: the PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Heal Policy Manag."},{"key":"B122","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/archderm.139.6.795","article-title":"Appraising systematic reviews and meta-analyses","volume":"139","author":"Bigby","year":"2003","journal-title":"Arch Dermatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14737175.2019.1653760","article-title":"Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review","volume":"19","author":"Naranjo","year":"2019","journal-title":"Expert Rev Neurother."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.2337\/diacare.28.10.2378","article-title":"Diabetic peripheral neuropathy and depressive symptoms: the association revisited","volume":"28","author":"Vileikyte","year":"2005","journal-title":"Diabetes Care."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.4088\/JCP.v67n0807","article-title":"Comorbidity of fibromyalgia and psychiatric disorders","volume":"67","author":"Arnold","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B126","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1053\/j.gastro.2003.10.040","article-title":"Psychological and cognitive variables affecting treatment outcomes for urinary and fecal incontinence","volume":"126","author":"Heymen","year":"2004","journal-title":"Gastroenterology."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18112483","article-title":"Analgesic mechanisms of antidepressants for neuropathic pain","volume":"18","author":"Obata","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.10.002","article-title":"Integrating the monoamine, neurotrophin and cytokine hypotheses of depression - a central role for the serotonin transporter?","volume":"147","author":"Haase","year":"2015","journal-title":"Pharmacol Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/NDT.S91311","article-title":"The noradrenergic paradox: implications in the management of depression and anxiety","volume":"12","author":"Montoya","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B130","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fpsyt.2019.00286","article-title":"Dysfunction in serotonergic and noradrenergic systems and somatic symptoms in psychiatric disorders","volume":"10","author":"Liu","year":"2019","journal-title":"Front Psychiatry."},{"key":"B131","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fnbeh.2014.00099","article-title":"Common mechanisms of pain and depression: are antidepressants also analgesics?","volume":"8","author":"Nekovarova","year":"2014","journal-title":"Front Behav Neurosci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"F264","DOI":"10.1152\/ajprenal.90241.2008","article-title":"Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats","volume":"295","author":"Miyazato","year":"2008","journal-title":"Am J Physiol - Ren Physiol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1527-3458.2002.tb00234.x","article-title":"Duloxetine pharmacology: Profile of a dual monoamine modulator","volume":"8","author":"Karpa","year":"2002","journal-title":"CNS Drug Rev."},{"key":"B135","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41386-019-0523-4","article-title":"Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study","volume":"45","author":"Lisinski","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"B136","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/00912700022008810","article-title":"Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor","volume":"40","author":"Sharma","year":"2000","journal-title":"J Clin Pharmacol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/TCRM.S17428","article-title":"Duloxetine in the management of chronic musculoskeletal pain","volume":"8","author":"Smith","year":"2012","journal-title":"Ther Clin Risk Manag."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e106907","DOI":"10.1371\/journal.pone.0106907","article-title":"The association of depression and anxiety with pain: a study from NESDA","volume":"9","author":"De Heer","year":"2014","journal-title":"PLoS ONE."},{"key":"B139","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31887\/DCNS.2003.5.2\/macrocq","article-title":"Alcohol, nicotine, caffeine, and mental disorders","volume":"5","author":"Crocq","year":"2003","journal-title":"Dialogues Clin Neurosci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/jcr.2012.0018","article-title":"Effects of alcohol, coffee, and tobacco, alone or in combination, on physiological parameters and anxiety in a young population","volume":"2","author":"Vinader-Caerols","year":"2012","journal-title":"J Caffeine Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/s-2008-1073173","article-title":"The influence of smoking on the serum level of duloxetine","volume":"41","author":"Fric","year":"2008","journal-title":"Pharmacopsychiatry."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1365-2036.2010.04449.x","article-title":"Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network","volume":"32","author":"Vuppalanchi","year":"2010","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.554899\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T22:38:25Z","timestamp":1618007905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.554899\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":142,"alternative-id":["10.3389\/fpsyt.2020.554899"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.554899","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"article-number":"554899"}}